Journal Club discussion of “Angiotensin system inhibitors may improve outcomes of patients with castration-resistant prostate cancer during abiraterone acetate treatment” – Front Oncol 2021

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Michał Wilk - Medical oncologist, working at the Department of Oncology of the European Health Center in Otwock, Poland. Member of the International Cardio-Oncology Society and European Society for Medical Oncology. The area of interest includes prostate cancer treatment and its cardiac complications and geriatric oncology.

Sebastian Szmit graduated from the Military Medical Academy in Poland. He began cardio-oncology activities in 2006 working for the Department of Oncology of the Military Institute of Medicine. He was appointed the executive editor of the Task Force of National Consultants in Cardiology and Clinical Oncology, and developed the first two Polish Recommendations on cardiovascular safety of patients with breast cancer (published in 2010) and lung cancer (published in 2012). Since 2012 he has served as the cardio-oncology consultant at the Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, at the Centre of Postgraduate Medical Education in Poland. In 2015 he was appointed as the scientific director of the "Oncology in Cardiology" training program. He is the cardio-oncology research coordinator for the Polish Lymphoma Research Group and the Polish National Oncology Network. He co-authored two educational books: "Hypertension-oncology: arterial hypertension in cancer disease" and "Cardiovascular complications in cancer patients" published in 2018 under auspices of the Polish Society of Clinical Oncology, Since 2019 he has been a Member of the Executive Committee of the Global Cardio-Oncology Summit (GCOS) and a Member of the Education & Training Advisory Committee of the International Cardio-Oncology Society (ICOS) and in 2020 he was awarded an Honorary Member of the Cardio-Oncology Society of Southern Africa (COSOSA), a Fellow of the International Cardio-Oncology Society (FICOS), and a Board Member of the European Society of Cardiology (ESC) Council of Cardio-Oncology. On May 26th 2021, Dr. Szmit was asked by the Scientific Council of the Centre of Postgraduate Medical Education to lead the newly created "Cardiooncology Department and Echocardiography Laboratory" based at the European Health Centre in Otwock (oncology center) and the Institute of Hematology and Transfusion Medicine in Warsaw.